Literature DB >> 2303976

Hepatotoxicity due to pemoline (Cylert): a report of two cases.

D S Pratt1, R S Dubois.   

Abstract

Pemoline (Cylert) is an agent used to treat attention deficit disorders and other behavioral syndromes. There have, however, been three published reports of mild hepatic dysfunction in five patients coincident with pemoline therapy. We report two further cases of probable pemoline hepatotoxicity. One case involved a mild aminotransferase elevation in a 6-year-old who was on pemoline for 5 months. The second case, in an 11-year-old, developed hepatic failure with marked prolongation in prothrombin time nonresponsive to parenteral vitamin K, deep jaundice, and submassive hepatic necrosis. This patient had a long history of pemoline usage. Pharmacokinetics are briefly discussed. A spectrum of hepatic disease due to pemoline is considered and the importance of obtaining aminotransferase values before, during initiation, and throughout treatment is stressed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2303976     DOI: 10.1097/00005176-199002000-00016

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  4 in total

1.  Sleepiness Versus Sleeplessness: Shift Work and Sleep Disorders in the Primary Care Setting.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

2.  Central Stimulant Treatment of Childhood Attention Deficit Hyperactivity Disorder : Issues and Recommendations from a US Perspective.

Authors:  D J Safer
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 3.  Benefits and risks of pharmacotherapy for narcolepsy.

Authors:  Merrill M Mitler; Roza Hayduk
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

4.  A surveillance method for the early identification of idiosyncratic adverse drug reactions.

Authors:  Fatma A Etwel; Michael J Rieder; John R Bend; Gideon Koren
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.